With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5061-21-2,2-Bromo-4-butanolide,as a common compound, the synthetic route is as follows.
5061-21-2, General procedure: Anhydrous K2CO3 (5 equiv) was added to the solution of relevantamine (1 equiv) and tetrabutylammonium bromide (TBAB)(0.01 equiv) in the acetonitrile and the mixture was stirred at at0 C for 1.5 h. Then a solution of 3-bromodihydrofuran-2(3H)-one(8) or 3-bromo-5-methyldihydrofuran-2(3H)-one (9) (1 equiv)was added dropwise and stirring was continued for 12-48 h atroom temperature. After the reaction was completed, the precipitatewas filtered off and the filtrate was concentrated under vacuum.Obtained crude products were purified by columnchromatography. Reagents and conditions: 4.85mmol 2 (1.22g), 24.25mmol K2CO3 (3.35g), 0.05mmol TBAB (0.02g), 4.85mmol 8 (0.80g), 20ml MeCN, 20h; purification by column chromatography (S5); Yield 72%; yellow oil; Rf: 0.76 (S7); 1H NMR (300MHz, chloroform-d) delta ppm 1.27-1.39 (m, 2H(piperidine)) 1.54-1.65 (m, 2H(piperidine)) 2.15 (dt, J=11.41, 3.53Hz, 1H(piperidine)) 2.22-2.35 (m, 3H (piperidine)) 2.60 (td, J=11.41, 2.56Hz, 1H(CHCH)) 2.71-2.80 (m, 1H(NCHCH2CH2)) 2.95-3.02 (m, 1H(NCHCH2CH2)) 3.47-3.52 (d, 1H (CHCH)) 3.54-3.61 (t, 1H (NCH)) 4.17 (td, J=8.91, 7.82Hz, 1H(CH2CH2O)) 4.27-4.38 (m, 1H (CH2CH2O)) 7.07-7.41 (m, 10H(Ar)), ESI-MS (m/z) 336.2 [M+H]+.
As the paragraph descriping shows that 5061-21-2 is playing an increasingly important role.
Reference£º
Article; Kowalczyk, Paula; Sa?at, Kinga; Hoefner, Georg C.; Guzior, Natalia; Filipek, Barbara; Wanner, Klaus T.; Kulig, Katarzyna; Bioorganic and Medicinal Chemistry; vol. 21; 17; (2013); p. 5154 – 5167;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem